Patents Assigned to The Trustees of Columbia University of the City of New York
-
Patent number: 12144191Abstract: An internal-ion gated electrochemical transistor is provided. In some embodiments, the internal-ion gated electrochemical transistor comprises: a gate electrode, a source electrode, and a drain electrode; a channel formed between the source electrode and the drain electrode, wherein the channel comprises a conducting polymer, wherein the channel serves as a reservoir of positively charged mobile ions; and an ion membrane between the channel and the gate electrode, wherein: in an off state, at least a subset of the positively charged mobile ions are ionically bonded to negatively charged ions of the conducting polymer, and wherein in an on state, at least a subset of the positively charged mobile ions are unbonded from the negatively charged ions of the conducting polymer to induce a current within the channel, and wherein at least one of the off state and the on state is actuated by application of a voltage to the gate electrode.Type: GrantFiled: June 21, 2021Date of Patent: November 12, 2024Assignee: The Trustees of Columbia University in the City New YorkInventors: Dion Khodagholy, Georgios Spyropoulos
-
Patent number: 12140540Abstract: Exemplary computer-accessible medium, systems, and methods are described herein which can provide an excited fluorescence radiation. In accordance with certain exemplary embodiments of the present disclosure, an excited fluorescence radiation can be provided using a beam of a probe so as to excite a molecule to an excited state for a fluorescence emission to effectuate the excited fluorescence radiation. The molecule can be detected based on the fluorescence emission. For example, the beam of the probe can be either the near-infrared spectrum or the visible light spectrum.Type: GrantFiled: September 13, 2021Date of Patent: November 12, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: Wei Min, Lixue Shi, Hanqing Xiong, Lu Wei
-
Patent number: 12138490Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: April 6, 2022Date of Patent: November 12, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20240368664Abstract: The present disclosure relates to kits, compositions and methods for detecting fungal species, viruses and/or protein variants in a sample, e.g., a biological sample. For example, but not by way of limitation, the present disclosure provides living yeast biosensors that have been genetically engineered to detect fungal species, viruses and/or protein variants in a sample, e.g., a biological sample.Type: ApplicationFiled: November 17, 2023Publication date: November 7, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Virginia Cornish, Tea CRNKOVIC, Davida RIOS, Amirhossein JAFARIYAN, Marco FANTINI, Anton KOZYRYEV
-
Publication number: 20240366641Abstract: Provided herein are methods and compositions for treating and preventing vascular malformations including lymphatic, venous, capillary, arteriovenous, and combinations thereof. Methods of treatment and prevention include the administration of proteasome inhibitors, omipalisib, disulfiram, and agents which target genes in the PI3K/AKT/mTOR or RAS/RAF/MAPK pathways, including but not limited to Pik3ca, Pik3r3, Tsc2, Rasa1, Map2k2, and Glmn.Type: ApplicationFiled: July 15, 2024Publication date: November 7, 2024Applicant: The Trustees of Columbia University in the City of New YorkInventors: Carrie J. SHAWBER, June K. WU, Ajit MULEY
-
Patent number: 12132176Abstract: Materials such as poly(vinylidene fluoride) (PVDF) and lithium cobalt (III) oxide (LCO) are recovered and recycled from cathode films isolated from end-of-life batteries, including lithium-ion batteries. Cathode films are immersed in solution including N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidine (NMP), a tetrahydrofuran (THF):NMP mixture, or a THF:DMF mixture. The solution is able to dissolve PVDF, which can then be separated from LCO and a conductive substrate component of the cathode films via alumina column separation. A PVDF product can be precipitated and recovered, while the LCO and conductive substrate can be recovered directly from the alumina column separator. Both the PVDF and LCO are of suitable quality for use in new cathode films. Such recovery is shown to be achievable even at low solid to liquid ratio during the dissolution process.Type: GrantFiled: October 13, 2021Date of Patent: October 29, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: Lauren Elizabeth Marbella, Amrita Sarkar, Richard May
-
Publication number: 20240350669Abstract: Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. The inhibitor can be a small molecule such as indiximod, epacadostat, BMS-986205, navoximod, PF-0684003, KHK2455 or LY3381916 or epacadostat. The inhibitor can be used alone or in conjunctions with other chemotherapeutic agents. IDO1 can also be inhibited using a CRISP-CAS system. The inhibitor can be administered orally, intravenously, intramuscularly, topically, arterially, or subcutaneously.Type: ApplicationFiled: July 3, 2024Publication date: October 24, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Stavroula KOUSTENI, Marta GALÁN-DÍEZ
-
Publication number: 20240351928Abstract: A fungal culture is provided that incorporates concentrations of Fenton reactants and white rot fungi biomass. These components synergize to degrade recalcitrant organic compounds such as lignins, perfluorochemicals including PFOA, plastics, and related compounds, particularly with 1.5 mM H2O2, 1 mM Fe2+, and Phanerochaete chrysosporium exhibiting lignin degrading capabilities comparable to cultures of Fenton-only reaction mediums with significantly higher concentrations of hydrogen peroxide. Both the fungi and the Fenton reactants work to degrade the organic compounds. Additionally, the Fenton reactants impose oxidative stress on fast-growing microbial competitors such as E. coli, selectively inhibiting the competing bacteria and their disadvantageous effects on white rot fungi activity. The white rot fungi recycle Fe(II) ions to reduce Fenton reactant input burden. An electro-Fenton reaction process can further reduce this burden by replenishing H2O2.Type: ApplicationFiled: April 17, 2024Publication date: October 24, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Julian John Alexander VAN DER MADE, Kartik CHANDRAN, Elizabetth Amy LANDIS, Ruby LAI
-
Patent number: 12125593Abstract: The present subject matter relates to techniques for hierarchical deep transcoding. The disclosed system can include a processor that can be configured to receive a functional magnetic resonance imaging (fMRI) data and/or an extracranial electroencephalogram (EEG) data and reconstruct a latent source space from the fMRI data and/or the EEG data by decoding the EEG data and/or the fMRI data to a latent source space. The fMRI data and the EEG data can be simultaneously acquired.Type: GrantFiled: October 5, 2021Date of Patent: October 22, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul Sajda, Xueqing Liu
-
Patent number: 12123005Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.Type: GrantFiled: July 10, 2019Date of Patent: October 22, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Antonio Iavarone, Anna Lasorella, Raul Rabadan
-
Patent number: 12115140Abstract: The method of treating adenoid cystic carcinoma or other cancer tumors includes the administration of an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof, alone or in combination with other cancer treatment. Non-limiting examples of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid (commonly referred to as “BMS493”) and 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl] ethynyl]benzoic acid (commonly referred to as “AGN193109”). Alternatively, prior to administration of the inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling, a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling may be administered to the patient.Type: GrantFiled: August 2, 2021Date of Patent: October 15, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Piero D. Dalerba, Sara Viragova
-
Publication number: 20240337825Abstract: A switchable light transmission module is disclosed that includes a substrate having a first surface defining at least part of an enclosed volume, a porous layer disposed on the first surface and in fluid communication with the enclosed volume, and a reservoir in fluid communication with the enclosed volume. The reservoir is configured to supply a fluid to the sealed volume such that the fluid contacts the porous layer. The fluid has a refractive index that is close to the refractive index of the porous layer, has a high wettability for the porous layer, and does not dissolve the porous layer. When in a dry state, voids in the porous layer are filled with air which has a much different refractive index than the porous layer itself, resulting in a surface that is reflective and not very transmissive.Type: ApplicationFiled: February 7, 2024Publication date: October 10, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK CITYInventors: Jyotirmoy MANDAL, Yuan YANG, Nanfang YU
-
Publication number: 20240329490Abstract: The disclosed subject matter provides systems and methods for band-interleaving. An example system can include a tunable band interleaver based on a ring-assisted Mach-Zehnder interferometer (RAMZI). The RAMZI can include a predetermined number of an assist rings.Type: ApplicationFiled: April 3, 2024Publication date: October 3, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Keren Bergman, Asher Novick, Anthony Rizzo, Songli Wang
-
Publication number: 20240325794Abstract: The present subject matter relates to techniques for releasing extracellular vesicles. The disclosed system can include an ultrasound assembly configured to apply an ultrasound treatment to a target tissue of the subject, a sampling device configured to collect a sample from the subject, and an analysis device configured to analyze a biomarker in the sample. The ultrasound assembly can include an ultrasound transducer and a function generator.Type: ApplicationFiled: April 3, 2024Publication date: October 3, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Elisa E. Konofagou, Alec J. Batts, Alina R. Kline-Schoder
-
Publication number: 20240325984Abstract: Cation exchange membranes are prepared via facile methods to control sulfonation of polystyrene repeat units. An amount of sulfuric acid is reacted with an acetic anhydride to form an amount of acetyl sulfate. The acetyl sulfate is then added to a known concentration of polystyrene units in boiling dichloromethane (DCM) to form sulfonated polystyrene random copolymers, including a random distribution of sulfonated polystyrene repeats and unsulfonated polystyrene repeats, with sulfonation levels between about 0.07 and about 0.225. The sulfonation level can be controlled by adjusting reaction times, reaction temperatures, and sulfuric acid loading in the reaction mediums. These membranes, neutralized via alkali metals, exhibit high charge densities and low hydration degrees, and maintain high permselectivity under various high solution concentrations.Type: ApplicationFiled: March 27, 2024Publication date: October 3, 2024Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Ngai Yin YIP, Sanat K. KUMAR, Yuxuan HUANG, Marshall TEKELL
-
Patent number: 12104114Abstract: Ionic superatomic materials that can be solution-processed into completely amorphous and homogeneous thin films are disclosed herein. The amorphous materials disclosed herein have tunable compositions and have electrical conductivities of up to 300 siemens per meter, thermal conductivities of 0.05 watt per meter per degree Kelvin, and optical transparencies of up to 92%. Application of these thin-films are also provided herein.Type: GrantFiled: June 30, 2020Date of Patent: October 1, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: Colin Nuckolls, Jingjing Yang, Alexander D. Christodoulides, Boyuan Zhang, Qizhi Xu, Amirali Zangiabadi, Christine McGinn, Samuel Peurifoy, Lingyun Dai, Elena Meirzadeh, Michael Steigerwald, Xavier Roy, Ioannis Kymissis, Jonathan A. Malen
-
Publication number: 20240318218Abstract: Synthetic enzymatic cascades are provided that continuously produce adenosine triphosphate (ATP) from a variety of fuel sources. The cascades are prepared by expressing one or more NADH-dependent dehydrogenases, polyphosphate NAD+ kinases (PPNK), NADPH oxidases, and particular reversible ATP-NAD+ kinases (NADK). The NADH-dependent dehydrogenases oxidize fuel sources such as formate and methanol while converting NAD+ to NADH. The PPNKs convert the NADH to NADPH. The NADPH oxidases convert NADPH to NADP+. The NADKs then convert the NADP+ to NAD+ while also facilitating conversion of adenosine diphosphate (ADP) or adenosine monophosphate (AMP) to ATP. Human NADK exhibits high affinity for NAD+ and is thus impeded in the generation of ATP products via product inhibition. Thus, pigeon, duck, and cat NADK isoforms are implemented in the cascade instead. The cascades generate a low-cost, continuous source ATP product for use in numerous in vitro applications such as cell-free protein production.Type: ApplicationFiled: March 20, 2024Publication date: September 26, 2024Applicant: The Trustees of Columbia University in The City of New YorkInventors: Scott BANTA, Emma WILLETT
-
FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS
Publication number: 20240318245Abstract: This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides.Type: ApplicationFiled: March 21, 2024Publication date: September 26, 2024Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jingyue Ju, Dae Hyun Kim, Lanrong Bi, Qinglin Meng, Xiaoxu Li -
Patent number: 12098187Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: December 20, 2018Date of Patent: September 24, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 12100121Abstract: An exemplary system, method, and computer-accessible medium for detection of structural disorder(s) of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the structural disorder(s) of the patient(s) based on a GD contrast of the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map. The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), or (ii) a Gd-free MRI scan(s). The Gd contrast can be generated in the Gd enhanced map(s) using a T2-weighted MRI image of the portion(s). Structural disorder(s) can include Stroke, tumor, trauma, infection, Multiple sclerosis and/or other inflammatory disease.Type: GrantFiled: June 15, 2021Date of Patent: September 24, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jia Guo, Scott A. Small